Volume 28, Number 12—December 2022
Research
Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
Table 2
Antibody titers, vaccinia virus | Antibody titer, cowpox virus |
||||
---|---|---|---|---|---|
10 | 20 | 40 | 80 | 160 | |
10 | 3,443 (77.44) | 407 (9.15) | 4 (0.09) | 2 (0.04) | 1 (0.02) |
20 | 234 (5.26) | 85 (1.91) | 12 (0.27) | 5 (0.11) | 0 |
40 | 7 (0.16) | 77 (1.73) | 62 (1.39) | 12 (0.27) | 3 (0.07) |
80 | 0 | 4 (0.09) | 31 (0.70) | 21 (0.47) | 3 (0.07) |
160 | 0 | 1 (0.02) | 0 | 2 (0.04) | 2 (0.04) |
*Values are no. (%). Percentages were calculated according to 4,448 participants in France who had serum samples tested for antibodies against both vaccinia and cowpox viruses by using the seroneutralization assay.
Page created: October 14, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.